 - To determine which dose of alemtuzumab is efficient to eliminate minimal residual disease in peripheral blood and bone marrow i.e., to turn a clinical partial remission into a clinical complete remission CR, to turn a flow cytometry-positive CR into a flow cytometry-negative CR, or to turn a PCR-positive CR into a PCR-negative CR. 